<DOC>
	<DOCNO>NCT00144287</DOCNO>
	<brief_summary>This study evaluate safety tolerability tipranavir improve treatment option HIV type 1-infected patient previously treat whose treatment longer effective .</brief_summary>
	<brief_title>Safety Study Tipranavir Co-administered With Low-dose Ritonavir ( TPV/r ) Patients With Advanced HIV-1 Infection Limited Treatment Options</brief_title>
	<detailed_description>The purpose open label study assess safety tolerability tipranavir co-administered low-dose ritonavir ( 500 mg tipranavir/200 mg ritonavir BID ) HIV-1 infected patient triple antiretroviral class experience least two previous PI-containing regimen . The safety assessment perform evaluating : - The frequency treatment-emergent adverse event ( AEs ) , serious adverse event ( SAEs ) , additional safety laboratory parameter . - The occurrence PI class-specific AEs , hemorrhage , dyslipidemia , hepatic event , hyperglycemia , pancreatitis , rash . The efficacy assessment perform evaluating : - The quantity HIV-1 RNA - The CD4 cell count . Study Hypothesis : The purpose open label study assess safety tolerability tipranavir co-administered low-dose ritonavir ( 500 mg tipranavir/200 mg ritonavir BID ) HIV-1 infected patient triple antiretroviral class experience least two previous PI-containing regimen . Comparison ( ) : N.A .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>1 . Triple antiretroviral class experience patient least two previous PIbased regimen , fail intolerant currently approve HIV1 treatment 2 . Age &gt; = 18 year 3 . Patient willing use effective barrier method contraception duration study participation three month thereafter 4 . Patient voluntarily provide write informed consent participate , compliance local law 1 . Hypersensitivity active ingredient excipients tipranavir ritonavir 2 . Required use restrict medication 3 . Female patient childbearing potential : Have positive pregnancy test baseline Are breast feed . 4 . Any medical condition ( ) , opinion investigator , would interfere patientÂ´s ability participate adhere requirement protocol . 5 . Use investigational drug , within 30 day prior TPV/r initiation duration study participation . 6 . Hepatic impairment ( * ) evidence follow baseline laboratory finding : AST ALT &gt; 5X upper limit normal ( ULN ) total bilirubin &gt; 3.5X ULN AST ALT &gt; 2.5X ULN total bilirubin &gt; 2X ULN ( * ) Patients liver enzyme outside range restrict participation safety study data become available ongoing phase III clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>